Biogen Gets Patent Extension On MS Drug To 2026
NEW YORK (AP) — Biogen Idec Inc. has essentially received a 13-year patent extension on its biggest moneymaker, the multiple sclerosis drug Avonex, according to a Securities and Exchange Commission filing Tuesday.
Key patents dealing with the production of Avonex are scheduled to expire in 2013. But in the regulatory filing, Biogen said it has received a patent for the drug's use in treating a viral condition, disease, cancer or tumor until September 2026. The so-called method of use patent also includes the use of Avonex as a multiple sclerosis drug. Sales of Avonex reached $591.2 million during the most recent quarter. The company would not say whether this new patent blocks any potential competitors seeking to bring a generic version of the drug to market between 2013 and 2026. The patent win comes as the debate over a pathway for copies of pricey biotechnology-based drugs continues to work its way through Congress. Currently, there is no system set up for drug developers to make generic equivalents of biotechnology-based treatments. Unlike their chemical-based counterparts, biotech drugs are made using living organisms, making the production process more complicated than just copying a formula.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,322.70 | 1,097.31 | 2,182.48 | 34.97 |
Oil *
72.99
|
|
DOWN
118.42
|
DOWN
11.87
|
DOWN
24.43
|
DOWN
0.99
|
10 Yr
3.50%
SPDR Gold
107.90
|
|
-1.13%
|
-1.07%
|
-1.11%
|
-2.75%
|
Data delayed 20 minutes |














